Evidence Grade C — Moderate human evidence. 11 published studies, 10 human. 0 registered clinical trials.
Medically reviewed by a licensed medical professional
AOD-9604 is a modified fragment of human growth hormone that was investigated for obesity but failed a Phase IIb clinical trial. It received FDA GRAS status in 2014 as a food ingredient — this is not a drug approval and does not permit therapeutic claims. It is available through unregulated sources and is prohibited by WADA in sport.
AOD-9604 is also known by these brand and alternate names:
11 published studies: 10 human, 0 animal, 0 in-vitro, 5 reviews
AOD-9604 has no pharmaceutical authorisation. A Phase IIb obesity trial (536 patients, 12 weeks) of oral AOD-9604 failed to demonstrate significant weight loss compared to placebo. The obesity development programme was discontinued. The developer subsequently pivoted to investigating intra-articular injection for osteoarthritis with preliminary Phase IIa data.
The FDA GRAS status (2014) applies exclusively to its use as a food ingredient and does not constitute pharmaceutical approval, authorise therapeutic claims, or establish safety for injectable use. Products available through unregulated channels lack pharmaceutical quality assurance.
Research suggests a similar mechanism to HGH Fragment 176-191 — proposed fat metabolism effects through a non-growth-hormone-receptor pathway. Additional preclinical research has investigated potential effects on cartilage, but these observations are from animal and cell culture studies only. No mechanism has been validated through successful human clinical trials.
Research suggests the pivotal Phase IIb obesity trial (536 patients, 12 weeks) of oral AOD-9604 failed to demonstrate significant weight loss compared to placebo. The obesity development programme was discontinued. Subsequent research has pivoted to investigating intra-articular injection for osteoarthritis, with only preliminary Phase IIa data. The FDA GRAS status applies exclusively to use as a food ingredient and does not constitute drug approval, authorise therapeutic claims, or establish safety for injection. This distinction is frequently misrepresented in marketing from unregulated sources. Products from unregulated channels lack pharmaceutical quality assurance.
PeptideTrace tracks 0 registered clinical trials for AOD-9604 sourced from ClinicalTrials.gov.
No trials registered on ClinicalTrials.gov for this compound.
AOD-9604 is modified HGH Fragment 176-191 with Tyr at C-terminus and disulfide modification. MW ~1,815 Da. Developed by Metabolic Pharmaceuticals/CalzTech (Australia). GRAS status FDA 2014 as food ingredient (not drug). Not approved as pharmaceutical. WADA prohibited 2013.
Research suggests lipolysis stimulation and lipogenesis inhibition via non-GH receptor mechanism. Proposed beta-3 adrenergic/HSL enhancement. Additional: cartilage repair activity (increased proteoglycan synthesis, reduced degradation in canine OA and chondrocyte studies). Fat-reduction and cartilage-repair activities proposed as independent mechanisms.
No pharmaceutical authorization. Phase IIb obesity (N=536, 12 weeks): oral AOD-9604 failed — weight loss 1.9 vs. 1.4 kg placebo (P=NS). Development discontinued for obesity. CalzTech pivoted to intra-articular OA with preliminary Phase IIa results. FDA GRAS 2014 as food ingredient.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 34 vendor listings
View pricing data across vendors and countries for AOD-9604
Semaglutide is one of the most extensively studied peptide medications available today, with clinical trial data spanning over 50,000 patients. It is sold as Ozempic for type 2 diabetes (approved 2017), Rybelsus as an oral tablet for diabetes (approved 2019), and Wegovy for weight management (approved 2021). Wegovy has since received additional approvals for reducing heart attack and stroke risk, for use in adolescents aged 12 and older, and for liver disease related to obesity. In clinical trials, patients taking Wegovy lost an average of 14.9% of their body weight over 68 weeks, and the SELECT trial demonstrated a 20% reduction in major cardiovascular events such as heart attack and stroke. Research is now exploring its potential in early Alzheimer's disease. The main side effects are gastrointestinal, particularly nausea, and a key limitation is that most weight tends to return after stopping treatment.
Bimagrumab is in Phase II/III development (not yet approved). A Phase II trial (75 patients with type 2 diabetes and obesity) showed 20.5% fat mass reduction with 3.6% lean mass increase — essentially reshaping body composition without net appetite suppression. The BELIEVE Phase IIb trial (507 patients) showed that bimagrumab plus semaglutide achieved 22% weight loss with the weight lost being 88% fat — significantly better body composition than semaglutide alone. Bimagrumab is not a peptide. Its strategic significance is as a combination partner to address the muscle loss problem inherent in weight loss with current obesity drugs. Eli Lilly's acquisition positions it alongside tirzepatide.
Pemvidutide is in Phase II/III development (not yet approved). In the MOMENTUM Phase II trial (391 patients, 48 weeks), the 2.4 mg dose achieved 15.6% weight loss. Body composition analysis showed 78% of weight lost was fat mass, with only 22% lean mass — a favourable ratio. A Phase IIb MASH trial (212 patients) showed MASH resolution in up to 75% of patients at the highest dose. Pemvidutide's balanced receptor profile and no-titration dosing regimen represent potential practical advantages. The high rate of MASH resolution in Phase II positions it as a candidate for liver disease indications alongside obesity.
Evidence Reviews
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
